3 Phase III clinical trials. 1 million+ injections.
Cingal® is a single‑injection treatment combining cross‑linked hyaluronic acid with triamcinolone hexacetonide for rapid onset and sustained relief in osteoarthritis of the knee.
Backed by Phase III clinical evidence
Phase III Trials
Cingal’s efficacy and safety profile is supported by three completed Phase III clinical trials.
OMERACT-OARSI Responders
89% were responders at Week 1, demonstrating early improvement maintained over time and 92% at Week 26, demonstrating both rapid onset and durable response (OMERACT-OARSI = validated responder criteria for OA clinical trials).
Single Injection
Comparable to or better than multi-injection viscosupplementation courses, with the clinical convenience of one visit.
13-01 Data on File | 16-02 Data on File | 19-01 Data on File
Two complementary actions. One intra-articular injection.
Cingal combines two well-established treatments into a single, ready-to-use formulation:
Component 1
Hyaluronic Acid (HA): Monovisc-based
Proprietary high-concentration, cross-linked hyaluronic acid, produced through bacterial fermentation (not avian-derived), restores viscoelastic properties in the osteoarthritic joint and supports longer-term mobility and function.
Component 2
Triamcinolone Hexacetonide (TH)
An approved, long-acting corticosteroid with approximately 21-day duration of action. Micronised TH is suspended directly in the HA gel, part of a proprietary process, to deliver rapid reduction in intra-articular inflammation.
Together, they provide quick symptom relief while supporting longer‑term mobility and function across treated joints.
A unique, integrated combination of hyaluronic acid and corticosteroid.
Designed for the way knee OA presents
Patients want relief they can feel now and results that last. Cingal is formulated to do both, with a proven combination that addresses inflammation and joint mechanics in one treatment.
- Rapid reduction in pain and stiffness
- Well-tolerated and clinically proven
- Sustained symptom improvement from a single injection
- Backed by Anika’s hyaluronic acid expertise
A practical option for active, symptomatic OA
Patient Considerations
Patients who may be considered for Cingal include those who:
- Have mild to moderate osteoarthritis of the knee (Kellgren-Lawrence Grade 1-3)
- Continue to experience symptoms despite conservative measures
- Are looking for rapid relief without repeated injections
Patient selection is the prescribing clinician’s responsibility. Refer to the full Instructions for Use(opens in a new tab) for complete prescribing information, contraindications, and warnings.
Key Contraindications
Cingal should not be used in patients with:
- Known hypersensitivity to hyaluronate preparations or any product components
- Infections or skin disease at or near the injection site
- Known bleeding disorders
Refer to the full IFU(opens in a new tab) for complete contraindications, warnings, and precautions.
Kellgren-Lawrence (K-L) grading system for osteoarthritis
Advanced science focused on joint health
Cingal is part of Anika’s portfolio of osteoarthritis pain management and hyaluronic acid technologies, developed with one aim: to help patients move better, sooner.
-
30+
Years of HA Research -
45+
Markets Worldwide -
1,000,000+
Cingal Injections Worldwide
Ready to review the evidence and prescribe Cingal?
Review full clinical evidence
Three phase III trials, economic data, safety profile, and clinical publications
Cingal availability
Find your regional distributor or contact our team to access Cingal in your market
